Christopher R Flowers, MD, MS
Jerkeman M et al. Initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-POLA-MINI-CHP and R-MINI-CHOP. EHA 2023;Abstract S227.
Palmer AC et al. Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin. N Engl J Med 2023;389(8):764-6. Abstract
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Westin J et al. Smart Start: Rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma. J Clin Oncol 2023;41(4):745-55. Abstract
Matthew Lunning, DO
Abramson JS. A new CAR takes a test drive in DLBCL. Blood 2023;141(20):2410-1. Abstract
Caimi PF et al. Long-term responses with loncastuximab tesirine: Updated results from LOTIS-2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large B-cell lymphoma. EHA 2023;Abstract P1132.
Caimi PF et al. The antiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy. Clin Lymphoma Myeloma Leuk 2022;22(5):e335-9. Abstract
Kamdar M et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022;399(10343):2294-308. Abstract
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640-54. Abstract
Neelapu SS et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2023;141(19):2307-15. Abstract
Qualls D et al. Tafasitamab and lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): Real world outcomes in a multicenter retrospective study. ASH 2022;Abstract 323.
Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43. Abstract
Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023;389(2):148-57. Abstract
Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: A paradigm shift? Blood 2022;139(18):2737-46. Abstract
Laurie H Sehn, MD, MPHO
Bannerji R et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 2022;9(5):e327-39. Abstract
Budde LE et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. J Clin Oncol 2022;40(5):481-91. Abstract
Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract
Falchi L et al. Metabolic response rates of epcoritamab + R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. ASCO 2023;Abstract 7519.
Karimi Y et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. ASCO 2023;Abstract 7525.
Kim WS et al. Effects of anti-CCR4 antibody (KW-0761) on regulatory T cells and natural killer cells in patients with cutaneous T-cell lymphoma. ASH 2022;Abstract 444.
Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2022;41(12):2238-47. Abstract
Thieblemont C et al. Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: A phase 2 study. EHA 2022;Abstract LB2364.
Walewski J et al. Odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from a prespecified analysis of the pivotal phase 2 study ELM-2. EHA 2023;Abstract P1115.